Type 2 diabetes mellitus with ketoacidosis without coma
Methodology & AI Transparency ⓘ
Type 2 diabetes mellitus with ketoacidosis without coma Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Cataloged under federal diagnostic code E11.10 in Diabetes & Glucose, Type 2 diabetes mellitus with ketoacidosis without coma requires hemoglobin A1c tracking [Type 2 diabetes mellitus with ketoacidosis without coma E11.10] so specialists can calibrate treatment intensity against Fasting Plasma Glucose [Type 2 diabetes mellitus with ketoacidosis without coma E11.10] benchmarks.
- 2 Real-world patient consensus: Diagnostic registry E11.10: Type 2 diabetes mellitus with ketoacidosis without coma is managed within Diabetes & Glucose.
- 3 Typical cash cost range: Primary evaluation for Type 2 diabetes mellitus with ketoacidosis without coma incorporates hemoglobin A1c tracking [Type 2 diabetes mellitus with ketoacidosis without coma E11.10] and symptom diary review.
- 4 Top reported side effects / signs: Longitudinal Type 2 diabetes mellitus with ketoacidosis without coma monitoring tracks Fasting Plasma Glucose [Type 2 diabetes mellitus with ketoacidosis without coma E11.10] toward 75 – 95 mg/dL (E11.10).
Ask our AI Specialists anything about Type 2 diabetes mellitus with ketoacidosis without coma
What Is Type 2 diabetes mellitus with ketoacidosis without coma?
Cataloged under federal diagnostic code E11.10 in Diabetes & Glucose, Type 2 diabetes mellitus with ketoacidosis without coma requires hemoglobin A1c tracking [Type 2 diabetes mellitus with ketoacidosis without coma E11.10] so specialists can calibrate treatment intensity against Fasting Plasma Glucose [Type 2 diabetes mellitus with ketoacidosis without coma E11.10] benchmarks.
Pathophysiology, Underlying Causes & Clinical Presentation
Mechanistic hallmarks of Type 2 diabetes mellitus with ketoacidosis without coma (E11.10) center on impaired incretin GLP-1/GIP in Type 2 diabetes mellitus with ketoacidosis without coma (E11.10: signaling). targeted diabetes & glucose interventions aim to normalize Fasting Plasma Glucose [Type 2 diabetes mellitus with ketoacidosis without coma E11.10].
Common Symptoms & Clinical Signs
- • Presentation of Type 2 diabetes mellitus with ketoacidosis without coma (E11.10): increased thirst [Type 2 diabetes mellitus with ketoacidosis without coma E11.10]
- • Secondary Type 2 diabetes mellitus with ketoacidosis without coma clinical sign: postprandial afternoon energy in Type 2 diabetes mellitus with ketoacidosis without coma (E11.10: crashes and carbohydrate)
- • Symptom flares in Type 2 diabetes mellitus with ketoacidosis without coma correlating with Fasting Plasma Glucose [Type 2 diabetes mellitus with ketoacidosis without coma E11.10] deviation outside 75 – 95 mg/dL (E11.10)
- • Functional diabetes & glucose impact requiring hemoglobin A1c tracking [Type 2 diabetes mellitus with ketoacidosis without coma E11.10] evaluation (E11.10)
Type 2 diabetes mellitus with ketoacidosis without coma Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | E11.10 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Type 1 & Type 2 Diabetes | NLM Clinical Tables |
| Diagnostic / Lab Marker: Fasting Plasma Glucose [Type 2 diabetes mellitus with ketoacidosis without coma E11.10] | 75 – 95 mg/dL (E11.10) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Fasting Insulin [Type 2 diabetes mellitus with ketoacidosis without coma E11.10] | 3.0 – 7.0 uIU/mL (E11.10) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: CGM Time-in-Range (70–140 in Type 2 diabetes mellitus with ketoacidosis without coma (E11.10: mg/dL)) | > 85% (E11.10) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Type 2 diabetes mellitus with ketoacidosis without coma
Treatment selection for Type 2 diabetes mellitus with ketoacidosis without coma depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Type 2 diabetes mellitus with ketoacidosis without coma)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Benefits and safety of empagliflozin as add-on to metformin for type 2: What a 4,256-Participant Study Found EMPA as add-on to MET was well tolerated and provided additional benefits beyond glucose lowering, such as weight loss and blood pressure reduction. European journal of clinical pharmacology • 2016-06-15 • Meta-Analysis | N = 4,256 | 99/100 | PMID 26832915 ↗ |
| New Insights on Is metformin still the most efficacious first-line oral hypoglycaemic drug in: What a 33,830-Participant Study Found This meta-analysis showed that repaglinide and metformin would be the most efficacious oral drugs for first-line single-drug treatment of T2DM. Obesity reviews : an official journal of the International Association for the Study of Obesity • 2019-01-15 • Meta-Analysis | N = 33,830 | 99/100 | PMID 30230172 ↗ |
| New Insights on Heart and blood vessel outcomes of liraglutide in patients with type 2: What a 14,608-Participant Study Found Our results suggest that liraglutide treatment decreases the risk of MACE, AMI, all-cause death and heart and blood vessel death among patients with type 2 diabetes. Medicine • 2019-11-15 • Meta-Analysis | N = 14,608 | 99/100 | PMID 31725627 ↗ |
| New Insights on Effect of metformin on microvascular outcomes in patients with type 2: What a 18,181-Participant Study Found There is no evidence of clinically significant beneficial effect of metformin therapy as compared to other glucose-lowering medications or placebo on the examined microvascular complications. Diabetes research and clinical practice • 2022-04-15 • Meta-Analysis | N = 18,181 | 99/100 | PMID 35247521 ↗ |
| New Insights on Benefits and safety of 11 sodium-glucose cotransporter-2 inhibitors at different: What a 9,144-Participant Study Found As add-on therapy, SGLT2is demonstrated favourable antidiabetic efficacy and acceptable safety. BMJ open • 2025-02-26 • Meta-Analysis | N = 9,144 | 99/100 | PMID 40010842 ↗ |
Type 2 diabetes mellitus with ketoacidosis without coma Patient Community & “People Like Me” Threads
Filter Type 2 diabetes mellitus with ketoacidosis without coma community threads and patient logs by age, biological sex, dosage, and treatment duration.